ONTXW - (Onconova Therapeutics Inc.)

 ONTXWのチャート


 ONTXWの企業情報

symbol ONTXW
会社名
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種   
概要 事業概要 --     Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.
本社所在地 --
代表者氏名
代表者役職名
電話番号
設立年月日 --
市場名 --
ipoyear ―年
従業員数 -
url
nasdaq_url https://www.nasdaq.com/symbol/ontxw
adr_tso
EBITDA EBITDA ー
終値(lastsale) 0.0445
時価総額(marketcap) 0
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 ONTXWのテクニカル分析


 ONTXWのニュース

   Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results  2020/08/12 20:05:00 GlobeNewswire
INSPIRE Phase 3 trial survival events reachedTopline data anticipated Q3-2020 Conference call and webcast scheduled today, August 12, at 4:30 p.m. ET …
   Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020  2020/08/07 12:00:00 GlobeNewswire
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, August 12
   Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis  2020/07/29 17:30:00 GlobeNewswire
Topline INSPIRE Results are Expected by the End of the Third Quarter of 2020
   Onconova files for NIH funding for studies of rigosertib in COVID-19 (NASDAQ:ONTX)  2020/07/27 12:25:37 Seeking Alpha
Onconova Therapeutics (NASDAQ:ONTX) has submitted an application to the National Institute of Allergy and Infectious Disease (NIAID) aimed at obtaining fun
   Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease  2020/07/27 12:00:00 Yahoo Finance
Preclinical experiments with rigosertib in cellular models demonstrate marked inhibition of SARS-CoV-2 replicationNEWTOWN, Pa., July 27, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products
   Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results  2020/08/12 20:05:00 GlobeNewswire
INSPIRE Phase 3 trial survival events reachedTopline data anticipated Q3-2020 Conference call and webcast scheduled today, August 12, at 4:30 p.m. ET …
   Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020  2020/08/07 12:00:00 GlobeNewswire
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, August 12
   Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis  2020/07/29 17:30:00 GlobeNewswire
Topline INSPIRE Results are Expected by the End of the Third Quarter of 2020
   Onconova files for NIH funding for studies of rigosertib in COVID-19 (NASDAQ:ONTX)  2020/07/27 12:25:37 Seeking Alpha
Onconova Therapeutics (NASDAQ:ONTX) has submitted an application to the National Institute of Allergy and Infectious Disease (NIAID) aimed at obtaining fun
   Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease  2020/07/27 12:00:00 Yahoo Finance
Preclinical experiments with rigosertib in cellular models demonstrate marked inhibition of SARS-CoV-2 replicationNEWTOWN, Pa., July 27, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products
   Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results  2020/08/12 20:05:00 GlobeNewswire
INSPIRE Phase 3 trial survival events reachedTopline data anticipated Q3-2020 Conference call and webcast scheduled today, August 12, at 4:30 p.m. ET …
   Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020  2020/08/07 12:00:00 GlobeNewswire
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, August 12
   Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis  2020/07/29 17:30:00 GlobeNewswire
Topline INSPIRE Results are Expected by the End of the Third Quarter of 2020
   Onconova files for NIH funding for studies of rigosertib in COVID-19 (NASDAQ:ONTX)  2020/07/27 12:25:37 Seeking Alpha
Onconova Therapeutics (NASDAQ:ONTX) has submitted an application to the National Institute of Allergy and Infectious Disease (NIAID) aimed at obtaining fun
   Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease  2020/07/27 12:00:00 Yahoo Finance
Preclinical experiments with rigosertib in cellular models demonstrate marked inhibition of SARS-CoV-2 replicationNEWTOWN, Pa., July 27, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products

 関連キーワード  (― 米国株 ONTXW Onconova Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)